Loading
companiesCompany
GV20 Therapeutics
GV20 Therapeutics is a US-based biotechnology company that leads 2 cancer trials in OnCo, testing the anti-IGSF8 antibody GV20-0251 in endometrial cancer, head and neck squamous cell carcinoma, melanoma and non-small-cell lung cancer.
Also called: GV20 Therapeutics
Overview
GV20 Therapeutics is a clinical-stage biotechnology company that uses its AI-driven STEAD platform, combining B-cell repertoire data, omics data and disease biology, to discover antibody targets and therapeutics. Its lead candidate GV20-0251 is a first-in-class antibody against the immune checkpoint IGSF8, in phase 1 in the United States and China. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT05669430 (phase 1/2, A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Par...) and NCT07070518 (phase 1/2, Study of GV20-0251 in Participants With Solid Tumor Malignancies). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Newton, Massachusetts, US
Scorecard
All companies#70of 1244 companies, score 61
- approved products +6
- targets +2
- modalities +2
- regions +7
- 24-month regulatory events +14
- registry trials +30
1 approved, 0 in phase 3, 0 earlier, 1 targets, 2,094 registry studies. Formula on the scorecards page.
Type
Stage
Startup
Website
ApprovedMonoclonal antibody (anti-PD-1)
Pembrolizumab · Keytruda / Keytruda Qlex (SC)
Pembrolizumab is a PD-1 blocking antibody approved in more than 40 settings, from melanoma and lung cancer to the first tumour-agnostic approval for mismatch-repair-deficient tumours in 2017, and before and after surgery in triple-negative breast cancer. A subcutaneous form arrived in 2025, and it is the backbone partner for ADCs and personalised neoantigen vaccines.
cancers
drugs
ApprovedMonoclonal antibody (anti-PD-1)
Pembrolizumab · Keytruda / Keytruda Qlex (SC)
trials
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor MalignanciesStudy of GV20-0251 in Participants With Solid Tumor Malignancies